Cellectis (CLLS) Cash from Operations (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.75% |
| Dec 31, 2025 | -559.45% |
| Sep 30, 2025 | 84.76% |
| Jun 30, 2025 | 39.92% |
| Mar 31, 2025 | -36,410.64% |
| Dec 31, 2024 | 99.19% |
| Sep 30, 2024 | -111.17% |
| Jun 30, 2024 | 323.80% |
| Mar 31, 2024 | -153.77% |
| Dec 31, 2023 | 353.66% |
| Sep 30, 2023 | 10.23% |
| Jun 30, 2023 | 32.77% |
| Mar 31, 2023 | -2,221.80% |
| Dec 31, 2022 | 95.32% |
| Sep 30, 2022 | -10.50% |
| Jun 30, 2022 | 35.62% |
| Mar 31, 2022 | -73.66% |
| Dec 31, 2021 | 30.71% |
| Sep 30, 2021 | -150.94% |
| Jun 30, 2021 | 70.38% |
| Mar 31, 2021 | -20.78% |
| Dec 31, 2020 | -32.33% |
| Sep 30, 2020 | -15.23% |
| Jun 30, 2020 | -1,624.28% |
| Mar 31, 2020 | 119.94% |
| Dec 31, 2019 | 67.71% |
| Sep 30, 2019 | -6.75% |
| Jun 30, 2019 | 5.28% |
| Mar 31, 2019 | -8.72% |
| Dec 31, 2018 | -37.24% |
| Sep 30, 2018 | -19.67% |
| Jun 30, 2018 | 37.21% |
| Mar 31, 2018 | -110.02% |
| Dec 31, 2017 | 38.60% |
| Sep 30, 2017 | 10.94% |
| Jun 30, 2017 | -6.87% |
| Mar 31, 2017 | -1,078.19% |
| Dec 31, 2016 | 187.28% |
| Sep 30, 2016 | 82.25% |
| Jun 30, 2016 | 50.29% |
| Mar 31, 2016 | -178.17% |
| Dec 31, 2015 | 640.62% |
| Sep 30, 2015 | 71.38% |
| Jun 30, 2015 | -1,197.27% |